Aditya Bardia

Aditya Bardia is a medical oncologist leading clinical investigation into ADCs across the spectrum of breast cancer HER2 expression, including the emerging HER2-ultralow concept defined as IHC >0 to <1+. As a co-investigator on DESTINY-Breast06, his work has helped extend the clinical relevance of T-DXd into even lower HER2 expression ranges. He is also a leading investigator in TROP2-directed ADC development and maintains a broad portfolio of early-phase trials in advanced breast cancer.